Celgene Corporation (CELG) Arthritis Drug Appears Effective, Safe After One Year: Study
10/28/2013 7:08:43 AM
Previously untreated patients experienced significant and lasting reductions in signs and symptoms of psoriatic arthritis when given Celgene Corp's experimental oral drug, apremilast, according to data from a late stage clinical trial. Patients taking either the 20 milligrams or 30 mg dose of apremilast twice a day had a statistically significant improvement in symptoms, such as painful, swollen joints, after 16 weeks of treatment compared with those who received a placebo, researchers said. Signs and symptoms of the painful disease continued to improve on apremilast through a year of treatment, according to data to be presented next week at the American College of Rheumatology meeting in San Diego.
Help employers find you! Check out all the jobs and post your resume.